In terms of prognosis, PAAD patients with a high frequency of PHLDA1 mRNA mutations had shorter OS and DFS (p < 0.05) (Figure 3E,F), but PHLDA2/3 amplification mutations did not significantly affect the OS and DFS of PAAD patients (Supplementary Figure S2). Here, PHLDA2 is linked to pancreatic adenocarcinoma.